Autopsy report · NCT01437787
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 6 months before it stopped.
- 289 participants enrolled.
- Results were posted on the registry 12 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Conditions
- Hematopoietic Neoplasm
- Interventions
- SAR302503; Placebo
- Participants
- 289
- Sites
- 101
- Countries
- Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.